QUALITY OF LIFE OF PATIENTS WITH CHRONIC KIDNEY DISEASE VD STAGES TREATED HEMODIALYSIS IN THE RELATIONSHIP WITH MELATONIN-FORMING DYSFUNCTION OF THE EPIPHYSIS

  • Vitaliy Kondratiuk National Medical University named after O. Bogomolets, head of Department, MD, Professor
  • Anna Petrova National Medical University named after O. Bogomolets, Ph.D., assistant
  • Olena Karpenko National Medical University named after O. Bogomolets, Ph.D., docent
Keywords: chronic kidney disease, melatonin, pineal gland, melatonin-forming function of the pineal gland, hemodialysis, quality of life

Abstract

Goal. To study the quality of life (QOL) in patients with end-stage chronic kidney disease (CKD) who are treated with hemodialysis (HD) and to determine its relationship with the melatonic function of the pineal gland.
Materials and methods. The study included 130 patients who are treated with the HD method (mean age 55 ± 13.7 years). QOL was assessed using the SF-36 questionnaire modified for patients with renal pathology. The concentration of melatonin in saliva was determined by the enzyme immunoassay using the Human MS (Melatonin Sulfate) ELISA Kit, Elabscience.
Results and discussion. QoL studies demonstrated its deterioration in 96% of the examined patients, to a greater extent due to the symptoms of “burdensome disease” and MPE disorders. Analysis of the total QOL indicator in patients with impaired MFE is 22.2% (p <0.001) lower than the obtained indicator in the comparison group. The result of the scale «burden of disease» and SF-12 groups with pineal gland dysfunction by 57% (p <0.001) and 44.5% (p <0.001), respectively. The result of the «physical total component» of the group of the main group is 58.4% (p <0.001) lower than the similar component of the comparison group. The sum of the scores of the patients in the main group for the «mental total component» is 32.3% (p <0.001) less than the result of patients with preserved the melatonic function of the pineal gland.
Conclusions. The relationship between the deterioration of QOL and the violation of MFE was established. Patients with HD with impaired MFE are characterized by lower values: total QOL, severity of the disease, SF-12 total «physical components» and «mental components» than in patients with preserved MFE by 22.2%, 57%, 44.5%, respectively, 58.4% and 32.3% (all p <0.001), which indicates the negative impact of disturbances in the circadian rhythms of melatonin on the quality of life of this severe cohort of patients.

References

1. Дудар І.О., Паламар Б.І., Красюк Е.К., Петрова А.С. Поширеність ХХН VД стадії у світі та в Україні. Здоров’я України. 2015 (3-4): 10-12.
2. Кондратюк В.Є., Петрова А.С. Оцінка якості сну та життя у пацієнтів з хронічною хворобою нирок, що знаходяться на лікуванні методом гемодіалізу. Актуальні проблеми нефрології. 2018. (24): 37-40.
3. Smirnov A.V. Zamestitel’naja pochechnaja terapija. Nefrologija. 2011; 1: 33-46. [In Russian].
4. Kondratiuk V., Petrova А. Characteristics of melatonin-forming disorders of the epiphysis in hemodialysis patients depending on clinical and demographic parameters. Ukrainian Journal of Nephrology and Dialysis. 2020; 1 (65): 36-47. doi: 10.31450/ukrjnd.1(65).2020.06
(https://ukrjnd.com.ua/index.php/journal/article/view/390/285 )
5. Sayaka Ishigaki, Naro Ohashi, Takashi Matsuyama, and other, Melatonin ameliorates intrarenal renin–angiotensin system in a 5/6 nephrectomy rat model. Clinical and Experimental Nephrology. November 2017. 22(3): 539-549. DOI: 10.1007/s10157-017-1505-7·
6. Кондратюк В.Є., Петрова А.С., Карпенко О.В. Характеристика мелатонінутворювальної функції епіфіза у пацієнтів з хронічною
хворобою нирок у термінальній стадії. Клінічна ендокринологія та ендокринна хірургія. 2019. (4): 94-102. DOI: https://doi.org/10.30978/CEES-2019-4-94
7. Byjean A. Boutin. How Can Molecular Pharmacology Help Understand the Multiple Actions of Melatonin: 20 Years of Research and Trends. November 21st 2018: 13-21. DOI:10.5772/intechopen.79524.
8. Jihwan Myung, Mei-Yi Wu, Chun-Ya Lee, Amalia Ridla Rahim,Vuong Hung Truong, Dean Wu, Hugh David Piggins, Mai-Szu Wu. The Kidney Clock Contributes to Timekeeping by the Master Circadian Clock. nt. J. Mol. Sci. 2019, 20(11), 2765; https://doi.org/10.3390/ijms20112765
9. Cipolla-Neto, Fernanda Gaspar do Amaral. Melatonin as a Hormone: New Physiological and Clinical Insights. Endocrine Reviews, Volume 39, Issue 6, December 2018: 990–1028. https://doi.org/10.1210/er.2018-00084.
10. Каладзе Н.Н., Слободян Е.И., Говдалюк А.Л. Эпифизарный гормон мелатонин и хроническая болезнь почек (обзор литературы и собственные исследования). Журнал «Здоровье ребенка» 2 (61). 2015: 183-188.
11. Кондратюк В.Є., Петрова А.С., Карпенко О.В. Клінічна оцінка порушень мелатонінутворювальної функції епіфізу та анемії у хво-
рих на хронічну хворобу нирок 5 стадії, що лікуються гемодіалізом. Нирки. 2020. 9(1): 20-28.
Published
2021-07-30
How to Cite
Kondratiuk , V., Petrova, A., & Karpenko, O. (2021). QUALITY OF LIFE OF PATIENTS WITH CHRONIC KIDNEY DISEASE VD STAGES TREATED HEMODIALYSIS IN THE RELATIONSHIP WITH MELATONIN-FORMING DYSFUNCTION OF THE EPIPHYSIS. Actual Problems of Nephrology, (28), 37-45. https://doi.org/10.37321/nefrology.2021.28-04